{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.5"},{"groupId":"OG001","value":"59.4"},{"groupId":"OG002","value":"39.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"33"}],"units":"Participants"}],"description":"The percentage of patients reporting a RECIST confirmed response and/or a CA-125 response (in the absence of progression). A CA-125 response was defined as a confirmed greater or equal to 50% reduction in CA-125.","groups":[{"description":"Olaparib (AZD2281) 200 mg oral capsules twice daily","id":"OG000","title":"Olaparib 200 mg bd"},{"description":"Olaparib (AZD2281) 400 mg oral capsules twice daily","id":"OG001","title":"Olaparib 400 mg bd"},{"description":"Liposomal doxorubicin 50 mg/m2 intravenously every 4 weeks","id":"OG002","title":"Liposomal Doxorubicin"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"At the time that 57 PFS events had occurred (Data cut-off for primary analysis of PFS: 15 September 2009)","title":"Confirmed RECIST Response and/or CA-125 Response","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}